Compare JNJ & MS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JNJ | MS |
|---|---|---|
| Founded | 1886 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 542.4B | 342.1B |
| IPO Year | 2003 | 2025 |
| Metric | JNJ | MS |
|---|---|---|
| Price | $275.23 | $217.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 16 |
| Target Price | $238.20 | ★ $337.93 |
| AVG Volume (30 Days) | ★ 5.7M | 2.6M |
| Earning Date | 04-14-2026 | 04-15-2026 |
| Dividend Yield | ★ 2.36% | 2.14% |
| EPS Growth | ★ 90.50 | 28.43 |
| EPS | 4.41 | ★ 6.90 |
| Revenue | N/A | ★ $34,275,000,000.00 |
| Revenue This Year | $6.63 | $12.22 |
| Revenue Next Year | $7.43 | $5.62 |
| P/E Ratio | $63.15 | ★ $31.36 |
| Revenue Growth | N/A | ★ 5.73 |
| 52 Week Low | $173.33 | $147.25 |
| 52 Week High | $281.07 | $232.25 |
| Indicator | JNJ | MS |
|---|---|---|
| Relative Strength Index (RSI) | 65.49 | 52.92 |
| Support Level | $263.83 | $206.04 |
| Resistance Level | N/A | $220.58 |
| Average True Range (ATR) | 5.07 | 4.36 |
| MACD | 0.40 | -0.07 |
| Stochastic Oscillator | 88.86 | 68.58 |
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Morgan Stanley is a massive global financial services firm, with offices in 42 countries and more than 82,000 employees as of year-end 2025. The firm cut its teeth in investment banking and institutional trading, where it maintains a strong presence today, but generates the lion share of its income from wealth and asset management franchises, where it boasted $9.3 trillion in client assets at the end of 2025. After reincorporation as a bank holding company in the wake of the global financial crisis, Morgan Stanley also boasts a top 10 banking franchise by deposits, with more than $400 billion in customer deposits, predominately attributable to cash sweeps from its wealth management and brokerage businesses.